Optimization of cyclosporine exposure utilizing C2 level monitoring in de novo renal transplant recipients: The Toronto general hospital experience

Transplantation Proceedings

Volumn 33, Issue 7-8, 2001, Pages 3098-3099

  Maham, N ^a   Cardella, C ^a   Cattran, D ^a   Fenton, S ^a   O'Grady, C ^a   Hamill, J ^a   Smith, R ^a   Cole, E ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; ARTICLE; CANADA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GASTROINTESTINAL SYMPTOM; GENERAL HOSPITAL; GRAFT REJECTION; HLA MATCHING; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; TOXICITY;

CYCLOSPORINE; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0035671414     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(01)02320-X     Document Type: Article

References (5)

1. Belitsky P: Transplant Proc 32(suppl):10S, 2000
2. Mahalati K, et al: J Am Soc Nephrol 12:828, 2001
3. Keown P, et al: Am J Transplant (in press)
4. Levy G, et al: Transplantation 69(suppl):S387, 2000
5. Cole E, et al: Transplantation 57:60, 1994